To sN­DA or NDA? Aldeyra clears a sec­ond PhI­II for sea­son­al al­ler­gy eye drop

Aldeyra said its eye drop was bet­ter than the com­para­tor at re­duc­ing oc­u­lar itch­ing, red­ness and tear­ing, which means it has now cleared two Phase III tri­als for al­ler­gic con­junc­tivi­tis.

The drug is set to get an FDA de­ci­sion by Nov. 23 in dry eye dis­ease, with Aldeyra look­ing to go up against No­var­tis’ Xi­idra and Ab­b­Vie’s Resta­sis. With new da­ta on Thurs­day, Aldeyra CEO Todd Brady told an­a­lysts that the com­pa­ny thinks it has what’s need­ed for ap­proval in al­ler­gic con­junc­tivi­tis. Now the biotech just has to de­cide whether to sub­mit it as a sup­ple­men­tal NDA or carve out its own NDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER